Moderators: Jesspro
Search This Board: 
Created: 04/23/2010 03:30:06 PM - Followers: 222 - Board type: Free - Posts Today: 0
Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need.

*Aurinia Pharmaceuticals Inc.
http://www.auriniapharma.com/
 

Pipeline

 

Pipeline

Candidate & Indication Development Stage
Preclinical Phase 1 Phase 2 Phase 3 Market
VOCLOSPORINLupus Nephritis (LN)
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Market Phase not started

Aurinia is committed to working in areas of high unmet medical need and is poised to deliver the first approved therapy in the U.S. and Europe for the treatment of lupus nephritis, or LN.

The Voclosporin Advantage

Voclosporin, an investigational drug, is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with clinical data in over 2,000 patients across indications. Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action that has the potential to improve near- and long-term outcomes in lupus nephritis (LN) when added to standard of care mycophenolate mofetil (MMF). It has been granted “fast track status” by the U.S. Food & Drug Administration (FDA).

Voclosporin Could Transform the LN treatment Landscape

Voclosporin has the potential to become a best in class medication and the first approved treatment for LN in the U.S. and Europe, effectively altering the current treatment paradigm for the disease.

Advantages of Voclosporin Combined with Standard of Care (SoC)

Our clinical data suggests that adding voclosporin to the current SoC of MMF for the treatment of lupus nephritis (LN) will yield superior results to using the standard of care alone.

Additionally, voclosporin may prove to be an ideal therapy for lupus nephritis due to advantages such as:

  • Improved efficacy
    Increased safety
    Oral administration
    Improved average time to renal response or remission
    Improved duration of renal response
    Reduction in steroid burden
    Potential first line add-on to MMF
    Fewer toxic immunosuppressants required
Benefits of Voclosporin

Potential Benefits of Voclosporin

In clinical trials, Voclosporin has been shown to be especially effective in the presence of low dose steroids with rapid reduction of LN inflammatory markers and overall improved renal stability.

The list of potential product benefits includes:

LN Critical Need Voclosporin (based on AURA Results)
Control of Active Disease
Rapid Disease Control
Lower Steroid Burden
Impact on Extra-renal disease
Convenient Treatment Regimen

In previous studies, over 2000 patients have been treated with Voclosporin with no abnormal or unexpected SAE’s

Well Characterized Safety Profile

Efficacy of calcineurin inhibition has already been established. Voclosporin has a well-characterized safety profile (over 2,000 patient exposures across multiple years) across indications.

No new safety signals were observed with the use of Voclosporin in LN patients; Voclosporin was well-tolerated and renal function remained stable in clinical studies. The overall safety profile is consistent with other immunosuppressive drugs.

 

PlusOneCoin Top Posts Free PlusOneCoin
No plusone'd posts yet. Be the first!
Post Subject
#15829
Grabbed more shares today. Looking forward to Cosa 09/23/2022 05:20:48 PM
#15828
All the WEF/Biden admin needs to do is greggors 09/23/2022 11:40:02 AM
#15827
Those who sell now, in my opinion, are Jesspro 09/22/2022 08:05:21 PM
#15826
Thanks Jess. I get a kick out rosemountbomber 09/22/2022 07:09:00 PM
#15825
Best post of the day: “I was wondering where biotech_researcher 09/22/2022 02:52:02 PM
#15824
His departure was rather abrupt. nsomniyak 09/21/2022 07:43:31 PM
#15823
Probably a bad point, I have swing shares Cosa 09/21/2022 04:25:29 PM
#15822
yak that is a good response thank you. cervelo 09/21/2022 04:23:57 PM
#15821
10 stocks to sell now. Jesspro 09/21/2022 03:55:25 PM
#15820
I was wondering where you were Cervelo!! Felt Newbie1421 09/20/2022 03:24:46 PM
#15819
It appears that Walbert was there only to nsomniyak 09/20/2022 02:55:59 PM
#15818
since the company wrote that and not Mr. cervelo 09/20/2022 02:45:09 PM
#15817
On September 19, 2022, Timothy P. Walbert, a longbear 09/20/2022 01:25:26 PM
#15816
Jess, I think that if that was the biotech_researcher 09/20/2022 11:32:44 AM
#15815
What Director left?? biotech_researcher 09/20/2022 11:28:46 AM
#15814
Excellent point Cosa, could not agree more Ganz 09/20/2022 09:43:19 AM
#15813
It’s not too far fetched that Voclosporin may Jesspro 09/20/2022 08:34:42 AM
#15812
I will defer to U as the board Whalatane 09/19/2022 09:20:06 PM
#15811
Yes, this was all priced in. No rosemountbomber 09/19/2022 07:22:51 PM
#15810
Jess etc all, does the departure of the longbear 09/19/2022 05:22:18 PM
#15809
50% swing opportunity here. The 3rd quarter Cosa 09/19/2022 04:56:11 PM
#15808
Was EU approval in doubt ? The challenge Whalatane 09/19/2022 03:40:24 PM
#15807
Nope. The issues with KZR are 1) Whalatane 09/19/2022 03:33:21 PM
#15806
Longbear. Thanks for that link. I bought a biotech_researcher 09/19/2022 03:26:13 PM
#15805
Jess, I bought in on 9/15 as my biotech_researcher 09/19/2022 03:24:44 PM
#15804
Geez BR. How could anyone believe you anymore? Jesspro 09/19/2022 03:06:55 PM
#15803
KZR is selling on the news! thesaud 09/19/2022 03:00:06 PM
#15802
Its a sell the news event Whalatane 09/19/2022 02:18:51 PM
#15801
Weak market response so I dumped my shares biotech_researcher 09/19/2022 02:00:08 PM
#15800
This PR was expected since 9/15. Its delay longbear 09/19/2022 01:02:53 PM
#15799
This is big news, oddly quiet on the Ganz 09/19/2022 12:03:18 PM
#15798
no reaction to sp yet. thesaud 09/19/2022 11:43:55 AM
#15797
https://finance.yahoo.com/news/aurinia-announces-european-commission-approval-15 Jesspro 09/19/2022 11:28:38 AM
#15796
JUST GOT AN ALERT! It’s approved. Jesspro 09/19/2022 11:18:47 AM
#15795
The article just says EU marketing authorization decision longbear 09/19/2022 11:02:15 AM
#15794
Probably be announced on Friday 23 at the close… greggors 09/18/2022 09:02:45 PM
#15793
yup thesaud 09/18/2022 06:28:19 PM
#15792
Thanks. So according to the article decision rosemountbomber 09/18/2022 03:51:07 PM
#15791
On the 15th when the alert came up longbear 09/17/2022 08:39:55 AM
#15790
[this article is from 7/22/2022 thesaud 09/17/2022 06:52:12 AM
#15789
I thought somebody here said the 22nd. Jesspro 09/16/2022 06:55:56 PM
#15788
I thought the EU decision was today for Lupy? biotech_researcher 09/16/2022 03:17:23 PM
#15787
Parties could also agree for a buyout Jesspro 09/15/2022 06:57:14 PM
#15786
Within 24 hours biotech_researcher 09/15/2022 06:24:36 PM
#15785
theorized BR. That’s his gut feeling. If a Jesspro 09/15/2022 06:23:38 PM
#15784
But, Jess said they were bought out.. biotech_researcher 09/15/2022 05:42:48 PM
#15783
They have a thousand ways of doing it, Jesspro 09/15/2022 04:54:09 PM
#15782
More likely, there could have been some preliminary nsomniyak 09/15/2022 04:50:50 PM
#15781
thanks longbear, why no PR from aurinia? maybe tomorrow thesaud 09/15/2022 04:36:42 PM
#15780
“One poster in ST has theorized that the biotech_researcher 09/15/2022 04:30:30 PM
Post Subject